Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss

TLDR

Soluble amyloid‑β oligomers (ADDLs) are hypothesized to underlie memory failure in Alzheimer’s disease by inhibiting hippocampal long‑term potentiation, causing synapse loss, and potentially explaining the weak link between dementia and amyloid plaques. The study employed conformation‑specific antibodies raised against synthetic Aβ oligomers to demonstrate their accumulation in the frontal cortex of AD patients. AD brains contained up to 70‑fold higher levels of oligomers that are structurally identical to synthetic ones, bind hippocampal dendrites in ligand‑like clusters, act as high‑affinity ligands for a few non‑abundant proteins, and confirm that soluble Aβ oligomers are intrinsic to AD pathology, supporting new therapeutic strategies.

Abstract

A molecular basis for memory failure in Alzheimer's disease (AD) has been recently hypothesized, in which a significant role is attributed to small, soluble oligomers of amyloid β-peptide (Aβ). Aβ oligomeric ligands (also known as ADDLs) are known to be potent inhibitors of hippocampal long-term potentiation, which is a paradigm for synaptic plasticity, and have been linked to synapse loss and reversible memory failure in transgenic mouse AD models. If such oligomers were to build up in human brain, their neurological impact could provide the missing link that accounts for the poor correlation between AD dementia and amyloid plaques. This article, using antibodies raised against synthetic Aβ oligomers, verifies the predicted accumulation of soluble oligomers in AD frontal cortex. Oligomers in AD reach levels up to 70-fold over control brains. Brain-derived and synthetic oligomers show structural equivalence with respect to mass, isoelectric point, and recognition by conformation-sensitive antibodies. Both oligomers, moreover, exhibit the same striking patterns of attachment to cultured hippocampal neurons, binding on dendrite surfaces in small clusters with ligand-like specificity. Binding assays using solubilized membranes show oligomers to be high-affinity ligands for a small number of nonabundant proteins. Current results confirm the prediction that soluble oligomeric Aβ ligands are intrinsic to AD pathology, and validate their use in new approaches to therapeutic AD drugs and vaccines.